Online inquiry

IVTScrip™ mRNA-Anti-CD3E&MS4A1, BTCT4465A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4873MR)

This product GTTS-WQ4873MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD3E&MS4A1 gene. The antibody can be applied in Follicular lymphoma research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000733.4; NM_021950.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 931
UniProt ID P07766; P11836
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&MS4A1, BTCT4465A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ4873MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4728MR IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BOS161721
GTTS-WQ9285MR IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA IMMU-132
GTTS-WQ1280MR IVTScrip™ mRNA-Anti-EGFR, ABT-414(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABT-414
GTTS-WQ3411MR IVTScrip™ mRNA-Anti-ALB, aALB03(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA aALB03
GTTS-WQ5571MR IVTScrip™ mRNA-Anti-CD33, CDP-771(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CDP-771
GTTS-WQ9105MR IVTScrip™ mRNA-Anti-CD3E&PMEL, IMCgp100(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IMCgp100
GTTS-WQ9028MR IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMC RON-8
GTTS-WQ2965MR IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ANB020
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW